The efficacy and safety of adjunct bromocriptine therapy for levodopa-induced motor complications: A systematic review

Ramaker, C; Beek, W. J. T. Van De; Finken, Martijn J J; Hilten, Bob J. J. van

doi:10.1002/1531-8257(200001)15:1<56::aid-mds1010>3.0.co;2-2

Cited by 8 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Glutamate overactivity is believed to play a role in the production of dyskinesia10 and amantadine, a glutamate antagonist, has been reported to improve L ‐dopa‐induced dyskinesia in PD 57–60. Other N‐methyl‐D‐aspartate (NMDA) receptor antagonists may also modify dyskinesia in animal models 10.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical–Pathological study of levodopa complications

et al. 2002

View full text Add to dashboard Cite

We sought to determine the continued benefit and the pattern of motor complications of long-term levodopa treatment in Parkinson's disease. Patients were evaluated between 1968 and 1996. Only those who had an adequate levodopa trial and in whom autopsy revealed Lewy body Parkinson's disease were included. Total levodopa and mean daily dose were calculated in each case. Dyskinesia, wearing-off and on-off were collectively classified as motor adverse effects and reported as cumulative incidence. Forty-two patients (male, 30; female, 12) with mean 15.9 years of illness and 9.1 years follow-up received on average 500-mg levodopa daily over 9.8 years. Seventeen of 21 patients assessed during the last 18 months of life reported some motor benefit. Adverse effects were seen in 71.4% of patients. The most common was dyskinesia, in 61.9%; wearing-off in 35.7%; and on-off in 16.7% of patients. The earliest adverse effect was dyskinesia and the last to emerge was on-off. Isolated dyskinesia was seen in 35.7% and wearing-off in 7.1% of patients; 15.5% of patients developed dyskinesia after 2.6 years and 31% after 6.4 years on levodopa. We concluded that levodopa benefit declined and adverse effects increased with time. Dyskinesia was the earliest and the most common isolated adverse effect.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Wearing‐off is a common delayed complication of L ‐dopa therapy 7, 17, 44, 50, 60. There is no agreement on the minimum L ‐dopa dosing frequency or the degree of motor functional decline necessary to classify WO.…”

Section: Discussionmentioning

confidence: 99%

Clinical–Pathological study of levodopa complications

et al. 2002

View full text Add to dashboard Cite

show abstract

“…Bromocriptine was the first proposed dopaminergic agonist. It is used for the initial stages of PD because it delays the motor complications induced by long-term L-DOPA administration [36,37]. Avila-Costa et al [38] reported that the treatment with bromocriptine in the 6-OHDA-induced PD model attenuated the neurotoxic effect.…”

Section: Dopaminergic Agonistsmentioning

confidence: 99%

Melatonin Pretreatment Effect in a Parkinson Disease Experimental Model Induced by the Inhalation of Manganese in Mice

Avila-Costa¹,

Rodríguez-Alcántara²,

Gutiérrez-Valdez³

et al. 2022

Melatonin - Recent Updates

View full text Add to dashboard Cite

Parkinson disease (PD) is characterized by dopaminergic neuron loss of the substantia nigra compacta (SNc) and motor alterations. Here, we used the experimental model of inhalation of the mixture of manganese chloride (MnCl2) and manganese acetate Mn (OAc)3 for inducing PD. This model causes bilateral and progressive degeneration of the SNc dopaminergic neurons. Melatonin has antioxidant properties and it has been suggested that it contributes to the protective effect in neurodegenerative diseases. Therefore, we aimed to determine whether melatonin pretreatment protects against the Mn-induced alterations. Before Mn inhalation, three groups were trained for motor performance (1. control group, 2. Mn mixture exposed without pretreatment, and 3. melatonin-pretreated/Mn-exposed groups) for motor tests. The motor coordination was evaluated through the single-pellet reaching task and the beam-walking test. After five months, all the animals were sacrificed. Dendritic spines were counted in the striatum medium-sized spiny neurons and the number of TH-immunoreactive neurons in the SNc. Our findings show that the melatonin-pretreated animals had better motor coordination and less dendritic spines and TH immunoreactive neuron loss than the Mn-inhalation-only group. Therefore, melatonin pretreatment has a neuroprotective effect and could be considered an alternative treatment before the more severe PD symptoms appear.

show abstract

Bromocriptine/levodopa combined versus levodopa alone for early Parkinson's disease

Ramaker

Hilten²

2002

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

The efficacy and safety of adjunct bromocriptine therapy for levodopa-induced motor complications: A systematic review

Cited by 8 publications

References 18 publications

Clinical–Pathological study of levodopa complications

Clinical–Pathological study of levodopa complications

Melatonin Pretreatment Effect in a Parkinson Disease Experimental Model Induced by the Inhalation of Manganese in Mice

Bromocriptine/levodopa combined versus levodopa alone for early Parkinson's disease

Contact Info

Product

Resources

About